- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00176904
Stem Cell Transplant for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman line four times daily for 4 days, Cyclophosphamide intravenously via the Hickman line once a day for 4 days, and Anti-Thymocyte Globulin (ATG) intravenously (IV) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to subjects to help the new marrow "take" and grow.
On the day of transplantation, the donor's hematopoietic cells will be transfused via central venous catheter.
After hematopoietic cell transplant, subjects will then receive two drugs, cyclosporin and either methylprednisolone or Mycophenolate Mofetil (MMF). Cyclosporin and methylprednisolone or MMF are given to help prevent the complication of graft-versus-host disease and to decrease the chance that the new donor cells will be rejected.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center, University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy, Gaucher's disease, Fucosidosis, Wolman disease, Niemann-Pick disease and Batten disease (CLN3) who have a human leukocyte antigen (HLA)-identical or haplotype mismatched (at 1-3 antigens) related marrow, or umbilical cord blood donor. One or two umbilical cord blood (UCB) units may be used.
- Patients with GM1 gangliosidosis, Tay Sachs disease or Sandhoff disease who have a HLA-identical or 1 antigen mismatched related or unrelated donor, or suitably matched umbilical cord blood unit(s). One or two UCB units may be used.
- Patients with adrenoleukodystrophy must have magnetic resonance imaging (MRI) findings, neurological and neuropsychometric function consistent with the diagnosis, and for boys with parietal-occipital dysmyelination a performance intelligence quotient (IQ) ≥80. In cases, when the performance IQ is not ≥80, the protocol committee may recommend transplant if the patient's clinical condition and neuropsychometric status are deemed to be acceptable based upon consideration of such factors as age at onset of cerebral disease, magnitude of change in performance IQ and neurologic deficits.
- Patients with arylsulfatase A deficiency (Metachromatic Leukodystrophy) must have either the presymptomatic late infantile, juvenile or adult form of the disease and must have acceptable neurological and neuropsychometric function.
- Patients with galactocerebrosidase deficiency (Globoid Cell Leukodystrophy) must have acceptable neurological and neuropsychometric function.
- Patients with acid lipase deficiency (Wolman disease) must have a liver biopsy that documents no evidence of hepatic cirrhosis, and acceptable neurological and neuropsychometric function.
- Patients with fucosidase deficiency (Fucosidosis) must have acceptable neurological and neuropsychometric function.
- Patients with glucocerebrosidase deficiency (Gaucher's Disease) must have acceptable neurologic and neuropsychometric function.
- Patients with Batten's disease (CLN3) must have acceptable Neurological and neuropsychometric function.
- Absence of major organ dysfunction. Organ evaluation results as follows:
- Cardiac: ejection fraction >30%
- Renal: serum creatinine <2x normal or creatinine clearance 60 mL/min.
- Hepatic: total bilirubin <2x normal and Aspartate aminotransferase (AST) <2x normal
- Signed consent.
Exclusion Criteria:
- Patients with symptomatic late infantile form of metachromatic leukodystrophy.
- Patients with symptomatic infantile globoid leukodystrophy.
- Note: Patients with Hurler syndrome, mucopolysaccharidosis (MPS) VI, or Mannosidosis disease are no longer eligible for this protocol, but can be transplanted under protocol MT 9907 (NCT00176917 - Hematopoietic Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)).
- Pregnancy
- Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
- Patients or parents are psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance.
- Patients ≥ 50 kg may be at risk for having cell doses below the goal of ≥ 10 x 10^6 CD34 cells/kg and therefore will not be eligible to receive unrelated peripheral blood stem cells (PBSCs)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treated Patients
All patients treated with protocol regimen (chemotherapy and surgery).
|
The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases.
Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
Other Names:
Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant.
These three drugs are being given to help the new marrow "take" and grow.
METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 100 Days, 1 Year and 3 Years
|
Number of patients alive at designated timepoints after transplant.
|
100 Days, 1 Year and 3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Donor Engraftment
Time Frame: Day 100
|
Number of patients with full donor chimerism (state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease) by Day 100 post-transplant of at least 90%.
|
Day 100
|
Number of Patients With Grade II-IV Acute Graft-Versus-Host Disease
Time Frame: Day 100
|
Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant.
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.
|
Day 100
|
Number of Patients With Grade III-IV Acute Graft-Versus-Host Disease
Time Frame: Day 100
|
Number of patients who exhibited acute graft-versus-host disease by Day 100 post transplant.
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Grade I=mild, Grade II=moderate, Grade III=severe, Grade IV=life threatening.
|
Day 100
|
Number of Patients With Chronic Graft-Versus-Host Disease
Time Frame: 1 Year Post Transplant
|
Number of patients who exhibited chronic graft-versus-host disease by 1 Year post transplant.
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Chronic GVHD is an extension of this syndrome.
|
1 Year Post Transplant
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Lymphatic Diseases
- Demyelinating Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Endocrine System Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Neurodegenerative Diseases
- Carbohydrate Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Lipid Metabolism Disorders
- Dementia
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Frontotemporal Lobar Degeneration
- Leukoencephalopathies
- Histiocytosis, Non-Langerhans-Cell
- Histiocytosis
- Adrenal Gland Diseases
- Cholesterol Ester Storage Disease
- Hereditary Central Nervous System Demyelinating Diseases
- Peroxisomal Disorders
- Adrenal Insufficiency
- Sulfatidosis
- Frontotemporal Dementia
- Gangliosidoses, GM2
- Pick Disease of the Brain
- Metabolism, Inborn Errors
- Niemann-Pick Diseases
- Niemann-Pick Disease, Type A
- Niemann-Pick Disease, Type C
- Wolman Disease
- Adrenoleukodystrophy
- Neuronal Ceroid-Lipofuscinoses
- Gangliosidoses
- Gangliosidosis, GM1
- Leukodystrophy, Metachromatic
- Gaucher Disease
- Leukodystrophy, Globoid Cell
- Tay-Sachs Disease
- Fucosidosis
- Sandhoff Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Busulfan
- Antilymphocyte Serum
Other Study ID Numbers
- MT1995-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Niemann-Pick Disease
-
National Eye Institute (NEI)CompletedNiemann Pick DiseasesUnited States, United Kingdom
-
Cyclo Therapeutics, Inc.RecruitingNiemann-Pick Disease, Type C1United States, Spain, Israel, Taiwan, Brazil, Germany, Australia, Poland, Turkey, Italy, United Kingdom
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownNiemann-Pick Disease, Type C1China
-
Mandos LLCTerminatedNiemann-Pick Disease, Type CCosta Rica
-
Eunice Kennedy Shriver National Institute of Child...TerminatedNiemann-Pick Disease, Type C1United States
-
Cyclo Therapeutics, Inc.CompletedNiemann-Pick Disease, Type C1Israel, Sweden, United Kingdom
-
Vtesse, LLC, a Mallinckrodt Pharmaceuticals CompanyCompletedNiemann-Pick Disease, Type C1United States
-
Cyclo Therapeutics, Inc.Active, not recruitingNiemann-Pick Disease, Type C1United States
-
Mandos LLCCompletedNiemann-Pick Disease, Type CUnited States, Australia, United Kingdom, Germany, France, New Zealand, Singapore, Spain, Turkey
-
National Institute of Neurological Disorders and...CompletedBrain Neoplasm | Alzheimer's Disease | Niemann Pick DiseaseUnited States
Clinical Trials on Stem Cell Transplant
-
Azienda Ospedaliera San Giovanni BattistaCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
St. Jude Children's Research HospitalCompletedAnemia, Aplastic | Diamond-Blackfan Anemia | Amegakaryocytic Thrombocytopenia | Kostmann SyndromeUnited States
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
-
Royal Marsden NHS Foundation TrustCompleted
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Institutes of Health (NIH); National...RecruitingMyelofibrosisUnited States
-
Royal Marsden NHS Foundation TrustCompleted
-
University of Colorado, DenverCompletedHyperglycemia | Hypoglycemia | Stem Cell Transplant ComplicationsUnited States
-
National Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins LymphomaUnited States